Advertisement

The anticancer effects and mechanisms of fucoxanthin combined with other drugs

  • Zhengchao Wang
  • Hongmei Li
  • Minghao Dong
  • Pengfei ZhuEmail author
  • Yu CaiEmail author
Review – Cancer Research
  • 63 Downloads

Abstract

Purpose

Fucoxanthin (Fx) is a characteristic carotenoid present in brown seaweed that has been shown to have various benefits, including anticancer effects. In vitro studies demonstrated these various effects, including the suppression of cell viability, the promotion of apoptosis, and antiangiogenic, antiproliferative, and antimetastatic activity. Interestingly, combinations of Fx with other drugs have better effects than either Fx or other drugs alone. Although the antiproliferative and cancer prevention activities of the combination of Fx and other drugs are still unclear, several effects have been discovered, including the induction of apoptosis, cell cycle arrest at G1/G0, enhanced gap junctional intercellular communication, and the induction of autophagy via various mechanisms, such as decreasing P-gp, activating the CYP3A4 promoter, increasing reactive oxygen species and cellular uptake and suppressing the PI3K/Akt/NFκB pathway. In this review, we address the anticancer effects and mechanisms of the combination of Fx and other drugs in different types of cancer.

Methods

The relevant literature from PubMed and Web of Science databases is reviewed in this article.

Results

Fx combined with other drugs could enhance the effect of both Fx and the other drug or reduce the dose without reducing the effect, which may create more effective and less harmful therapeutic strategies.

Conclusion

Fx combined with other drugs has significant anticancer effects by various mechanisms and could be a potential therapeutic strategy for different types of cancer.

Keywords

Fucoxanthin Troglitazone 5-Fluorouracil Pregnane X receptor Imatinib 

Abbreviations

Fx

Fucoxanthin

Akt

Protein kinase B

mTOR

Mammalian target of rapamycin

Bcl-2

B-cell lymphoma 2

SAPK/JNK

c-Jun N-terminal kinases

JAK

Janus kinases

STAT

Signal transducer and activator of transcription protein family

NFκB

Nuclear factor kappa-light-chain-enhancer of activated B cells

MAPK

Mitogen-activated protein kinase

5-FU

5-Fluorouracil

PXR

Pregnane X receptor

WAF/Cip1

Cyclin-dependent kinase inhibitor 1

PPARγ

Peroxisome proliferator-activated receptor γ

ABC transporters

ATP-binding cassette transporters

MDR

Multidrug resistance protein

P-gp

P-glycoprotein

CS

Chitosan

GL

Glycolipid

NGs

Nanogels

ROS

Reactive oxygen species

Bax

Bcl-2-associated X protein

GADD45

Growth arrest and DNA-damage-inducible protein

CDK

Cyclin-dependent kinase

Cx

Connexin

CYP3A4

Cytochrome P450 3A4

SRC-1

Steroid receptor coactivator-1

ERCC1

Excision repair cross complementation 1

TP

Thymidine phosphorylase

ERK

Extracellular signal-regulated kinase

PI3K

Phosphoinositide 3-kinase

ALT

Adult T-cell leukemia

XIAP

X-linked inhibitor of apoptosis protein

cIAP2

Cellular inhibitor of apoptosis protein 2

IκBα

Nuclear factor of kappa light polypeptide gene enhancer in B-cell inhibitorα

Bcl-xL

B-cell lymphoma-extra large

CML

Chronic myelogenous leukemia

BCR

Breakpoint cluster region protein

ABL

Abelson murine leukemia viral oncogene homolog

Fxol

Fucoxanthinol

PTEN

Phosphatase and tensin homolog

TRAIL

Tumor necrosis factor-related apoptosis-inducing ligand

TNF

Tumor necrosis factor

Notes

Acknowledgements

We thank Rong Xu, Jiaxiong Ming, Huan Zhang, Yuyue Zuo, Department of Pharmacology, School of Basic Medicine, Tongji Medical College, Huazhong University of Science and Technology, for advice on the article.

Funding

This study was funded by National Natural Science Foundation of Wuhan (Grant no. WX18Q21 to YC).

Compliance with ethical standards

Conflict of interest

Authors declare that he/she have no conflict of interest.

Ethical approval

All applicable international, national, and/or institutional guidelines for the care and use of animals were followed.

References

  1. Almeida TP, Ferreira J, Vettorazzi A, Azqueta A, Rocha E, Ramos AA (2018) Cytotoxic activity of fucoxanthin, alone and in combination with the cancer drugs imatinib and doxorubicin, in CML cell lines. Environ Toxicol Pharmacol 59:24–33.  https://doi.org/10.1016/j.etap.2018.02.006 CrossRefGoogle Scholar
  2. Aoki H, Takada Y, Kondo S, Sawaya R, Aggarwal BB, Kondo Y (2007) Evidence that curcumin suppresses the growth of malignant gliomas in vitro and in vivo through induction of autophagy: role of Akt and extracellular signal-regulated kinase signaling pathways. Mol Pharmacol 72:29–39.  https://doi.org/10.1124/mol.106.033167 CrossRefGoogle Scholar
  3. Beppu F, Niwano Y, Sato E, Kohno M, Tsukui T, Hosokawa M, Miyashita K (2009a) In vitro and in vivo evaluation of mutagenicity of fucoxanthin (FX) and its metabolite fucoxanthinol (FXOH). J Toxicol Sci 34:693–698CrossRefGoogle Scholar
  4. Beppu F, Niwano Y, Tsukui T, Hosokawa M, Miyashita K (2009b) Single and repeated oral dose toxicity study of fucoxanthin (FX), a marine carotenoid, in mice. J Toxicol Sci 34:501–510CrossRefGoogle Scholar
  5. Brockman JA, Gupta RA, Dubois RN (1998) Activation of PPARgamma leads to inhibition of anchorage-independent growth of human colorectal cancer cells. Gastroenterology 115:1049–1055CrossRefGoogle Scholar
  6. Cepeda V, Fuertes MA, Castilla J, Alonso C, Quevedo C, Perez JM (2007) Biochemical mechanisms of cisplatin cytotoxicity. Anti-cancer Agents Med Chem 7:3–18CrossRefGoogle Scholar
  7. Das SK et al (2005) Fucoxanthin induces cell cycle arrest at G0/G1 phase in human colon carcinoma cells through up-regulation of p21WAF1/Cip1. Biochim Biophys Acta 1726:328–335.  https://doi.org/10.1016/j.bbagen.2005.09.007 CrossRefGoogle Scholar
  8. Das SK, Hashimoto T, Kanazawa K (2008) Growth inhibition of human hepatic carcinoma HepG2 cells by fucoxanthin is associated with down-regulation of cyclin D. Biochim Biophys Acta 1780:743–749.  https://doi.org/10.1016/j.bbagen.2008.01.003 CrossRefGoogle Scholar
  9. Dussault I, Forman BM (2002) The nuclear receptor PXR: a master regulator of “homeland” defense. Crit Rev Eukaryot Gene Expr 12:53–64Google Scholar
  10. Eid SY, El-Readi MZ, Wink M (2012) Carotenoids reverse multidrug resistance in cancer cells by interfering with ABC-transporters. Phytomedicine 19:977–987.  https://doi.org/10.1016/j.phymed.2012.05.010 CrossRefGoogle Scholar
  11. Gibson J, Iland HJ, Larsen SR, Brown CM, Joshua DE (2013) Leukaemias into the 21st century. Part 2: the chronic leukaemias. Intern Med J 43:484–494.  https://doi.org/10.1111/imj.12135 CrossRefGoogle Scholar
  12. Go RS, Adjei AA (1999) Review of the comparative pharmacology and clinical activity of cisplatin and carboplatin. J Clin Oncol 17:409–422.  https://doi.org/10.1200/jco.1999.17.1.409 CrossRefGoogle Scholar
  13. Gollamudi R, Gupta D, Goel S, Mani S (2008) Novel orphan nuclear receptors-coregulator interactions controlling anti-cancer drug metabolism. Curr Drug Metab 9:611–613CrossRefGoogle Scholar
  14. Gottesman MM, Fojo T, Bates SE (2002) Multidrug resistance in cancer: role of ATP-dependent transporters. Nat Rev Cancer 2:48–58.  https://doi.org/10.1038/nrc706 CrossRefGoogle Scholar
  15. Gu Y et al (2012) CaMKII gamma, a critical regulator of CML stem/progenitor cells, is a target of the natural product berbamine. Blood 120:4829–4839.  https://doi.org/10.1182/blood-2012-06-434894 CrossRefGoogle Scholar
  16. Hosokawa M, Kudo M, Maeda H, Kohno H, Tanaka T, Miyashita K (2004) Fucoxanthin induces apoptosis and enhances the antiproliferative effect of the PPARgamma ligand, troglitazone, on colon cancer cells. Biochim Biophys Acta 1675:113–119.  https://doi.org/10.1016/j.bbagen.2004.08.012 CrossRefGoogle Scholar
  17. Hou L-l, Gao C, Chen L, Hu G-q, Xie S-q (2013) Essential role of autophagy in fucoxanthin-induced cytotoxicity to human epithelial cervical cancer HeLa cells. Acta Pharmacol Sin 34:1403–1410.  https://doi.org/10.1038/aps.2013.90 CrossRefGoogle Scholar
  18. Iio K, Okada Y, Ishikura M (2011) Single and 13-week oral toxicity study of fucoxanthin oil from microalgae in rats. Shokuhin eiseigaku zasshi J Food Hyg Soc Jpn 52:183–189CrossRefGoogle Scholar
  19. Ishikawa C et al (2008) Antiadult T-cell leukemia effects of brown algae fucoxanthin and its deacetylated product, fucoxanthinol. Int J Cancer 123:2702–2712.  https://doi.org/10.1002/ijc.23860 CrossRefGoogle Scholar
  20. Jin Y, Qiu S, Shao N, Zheng J (2018) Fucoxanthin and tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) synergistically promotes apoptosis of human cervical cancer cells by targeting PI3K/Akt/NF-κB signaling pathway. Med Sci Monit 24:11–18.  https://doi.org/10.12659/msm.905360 CrossRefGoogle Scholar
  21. Kartalou M, Essigmann JM (2001) Mechanisms of resistance to cisplatin. Mutat Res 478:23–43CrossRefGoogle Scholar
  22. Kim K-N, Heo S-J, Kang S-M, Ahn G, Jeon Y-J (2010a) Fucoxanthin induces apoptosis in human leukemia HL-60 cells through a ROS-mediated Bcl-xL pathway. Toxicol In Vitro 24:1648–1654.  https://doi.org/10.1016/j.tiv.2010.05.023 CrossRefGoogle Scholar
  23. Kim KN, Heo SJ, Yoon WJ, Kang SM, Ahn G, Yi TH, Jeon YJ (2010b) Fucoxanthin inhibits the inflammatory response by suppressing the activation of NF-kappaB and MAPKs in lipopolysaccharide-induced RAW 264.7 macrophages. Eur J Pharmacol 649:369–375.  https://doi.org/10.1016/j.ejphar.2010.09.032 CrossRefGoogle Scholar
  24. Kim K-N et al (2013) Inhibition of tumor growth in vitro and in vivo by fucoxanthin against melanoma B16F10 cells. Environ Toxicol Pharmacol 35:39–46.  https://doi.org/10.1016/j.etap.2012.10.002 CrossRefGoogle Scholar
  25. Kotake-Nara E, Terasaki M, Nagao A (2005) Characterization of apoptosis induced by fucoxanthin in human promyelocytic leukemia cells. Biosci Biotechnol Biochem 69:224–227.  https://doi.org/10.1271/bbb.69.224 CrossRefGoogle Scholar
  26. Laroche-Clary A, Larrue A, Robert J (2000) Down-regulation of bcr-abl and bcl-x(L) expression in a leukemia cell line and its doxorubicin-resistant variant by topoisomerase II inhibitors. Biochem Pharmacol 60:1823–1828CrossRefGoogle Scholar
  27. Lebrecht D, Setzer B, Rohrbach R, Walker UA (2004) Mitochondrial DNA and its respiratory chain products are defective in doxorubicin nephrosis. Nephrol Dial Transplant 19:329–336CrossRefGoogle Scholar
  28. Lemke J, von Karstedt S, Zinngrebe J, Walczak H (2014) Getting TRAIL back on track for cancer therapy. Cell Death Differ 21:1350–1364.  https://doi.org/10.1038/cdd.2014.81 CrossRefGoogle Scholar
  29. Liu C-L, Huang Y-S, Hosokawa M, Miyashita K, Hu M-L (2009) Inhibition of proliferation of a hepatoma cell line by fucoxanthin in relation to cell cycle arrest and enhanced gap junctional intercellular communication. Chem Biol Interact 182:165–172.  https://doi.org/10.1016/j.cbi.2009.08.017 CrossRefGoogle Scholar
  30. Liu C-L, Lim Y-P, Hu M-L (2012) Fucoxanthin attenuates rifampin-induced cytochrome P450 3A4 (CYP3A4) and multiple drug resistance 1 (MDR1) gene expression through pregnane X receptor (PXR)-mediated pathways in human hepatoma HepG2 and colon adenocarcinoma LS174T cells. Mar Drugs 10:242–257.  https://doi.org/10.3390/md10010242 CrossRefGoogle Scholar
  31. Liu C-L, Lim Y-P, Hu M-L (2013) Fucoxanthin enhances cisplatin-induced cytotoxicity via NFκB-mediated pathway and downregulates DNA repair gene expression in human hepatoma HepG2 cells. Mar Drugs 11:50–66.  https://doi.org/10.3390/md11010050 CrossRefGoogle Scholar
  32. Liu Y, Zheng J, Zhang Y, Wang Z, Yang Y, Bai M, Dai Y (2016) Fucoxanthin activates apoptosis via inhibition of PI3K/Akt/mTOR pathway and suppresses invasion and migration by restriction of p38-MMP-2/9 pathway in human glioblastoma cells. Neurochem Res 41:2728–2751.  https://doi.org/10.1007/s11064-016-1989-7 CrossRefGoogle Scholar
  33. Maeda H, Hosokawa M, Sashima T, Funayama K, Miyashita K (2005) Fucoxanthin from edible seaweed, Undaria pinnatifida, shows antiobesity effect through UCP1 expression in white adipose tissues. Biochem Biophys Res Commun 332:392–397.  https://doi.org/10.1016/j.bbrc.2005.05.002 CrossRefGoogle Scholar
  34. Mahon FX, Deininger MW, Schultheis B, Chabrol J, Reiffers J, Goldman JM, Melo JV (2000) Selection and characterization of BCR-ABL positive cell lines with differential sensitivity to the tyrosine kinase inhibitor STI571: diverse mechanisms of resistance. Blood 96:1070–1079Google Scholar
  35. Martin L (2015) Fucoxanthin and its metabolite fucoxanthinol in cancer prevention and treatment. Mar Drugs 13:4784–4798.  https://doi.org/10.3390/md13084784 CrossRefGoogle Scholar
  36. Matheu A et al (2012) Oncogenicity of the developmental transcription factor Sox9. Cancer Res 72:1301–1315.  https://doi.org/10.1158/0008-5472.can-11-3660 CrossRefGoogle Scholar
  37. Mayne ST (1996) Beta-carotene, carotenoids, and disease prevention in humans. FASEB J 10:690–701CrossRefGoogle Scholar
  38. Mei C, Zhou S, Zhu L, Ming J, Zeng F, Xu R (2017) Antitumor effects of laminaria extract fucoxanthin on lung cancer. Mar drugs.  https://doi.org/10.3390/md15020039 Google Scholar
  39. Miki Y et al (2006) Expression of the steroid and xenobiotic receptor and its possible target gene, organic anion transporting polypeptide-A, in human breast carcinoma. Cancer Res 66:535–542.  https://doi.org/10.1158/0008-5472.can-05-1070 CrossRefGoogle Scholar
  40. Nishikawa S, Hosokawa M, Miyashita K (2012) Fucoxanthin promotes translocation and induction of glucose transporter 4 in skeletal muscles of diabetic/obese KK-A(y) mice. Phytomedicine 19:389–394.  https://doi.org/10.1016/j.phymed.2011.11.001 CrossRefGoogle Scholar
  41. Nishino H, Murakoshi M, Tokuda H, Satomi Y (2009) Cancer prevention by carotenoids. Arch Biochem Biophys 483:165–168.  https://doi.org/10.1016/j.abb.2008.09.011 CrossRefGoogle Scholar
  42. Park SS, Eom YW, Choi KS (2005) Cdc2 and Cdk2 play critical roles in low dose doxorubicin-induced cell death through mitotic catastrophe but not in high dose doxorubicin-induced apoptosis. Biochem Biophys Res Commun 334:1014–1021.  https://doi.org/10.1016/j.bbrc.2005.06.192 CrossRefGoogle Scholar
  43. Ravi H, Kurrey N, Manabe Y, Sugawara T, Baskaran V (2018) Polymeric chitosan-glycolipid nanocarriers for an effective delivery of marine carotenoid fucoxanthin for induction of apoptosis in human colon cancer cells (Caco-2 cells). Mater Sci Eng C Mater Biol Appl 91:785–795.  https://doi.org/10.1016/j.msec.2018.06.018 CrossRefGoogle Scholar
  44. Rwigemera A, Mamelona J, Martin LJ (2014) Inhibitory effects of fucoxanthinol on the viability of human breast cancer cell lines MCF-7 and MDA-MB-231 are correlated with modulation of the NF-kappaB pathway. Cell Biol Toxicol 30:157–167.  https://doi.org/10.1007/s10565-014-9277-2 CrossRefGoogle Scholar
  45. Saegusa M, Hashimura M, Suzuki E, Yoshida T, Kuwata T (2012) Transcriptional up-regulation of Sox9 by NF-kappaB in endometrial carcinoma cells, modulating cell proliferation through alteration in the p14(ARF)/p53/p21(WAF1) pathway. Am J Pathol 181:684–692.  https://doi.org/10.1016/j.ajpath.2012.05.008 CrossRefGoogle Scholar
  46. Sangeetha RK, Bhaskar N, Divakar S, Baskaran V (2010) Bioavailability and metabolism of fucoxanthin in rats: structural characterization of metabolites by LC-MS (APCI). Mol Cell Biochem 333:299–310.  https://doi.org/10.1007/s11010-009-0231-1 CrossRefGoogle Scholar
  47. Satomi Y, Nishino H (2009) Implication of mitogen-activated protein kinase in the induction of G1 cell cycle arrest and gadd45 expression by the carotenoid fucoxanthin in human cancer cells. Biochim Biophys Acta 1790:260–266.  https://doi.org/10.1016/j.bbagen.2009.01.003 CrossRefGoogle Scholar
  48. Shimada T, Kojima K, Yoshiura K, Hiraishi H, Terano A (2002) Characteristics of the peroxisome proliferator activated receptor gamma (PPARgamma) ligand induced apoptosis in colon cancer cells. Gut 50:658–664CrossRefGoogle Scholar
  49. Slattery ML, Benson J, Curtin K, Ma KN, Schaeffer D, Potter JD (2000) Carotenoids and colon cancer. Am J Clin Nutr 71:575–582.  https://doi.org/10.1093/ajcn/71.2.575 CrossRefGoogle Scholar
  50. Sugawara T, Baskaran V, Tsuzuki W, Nagao A (2002) Brown algae fucoxanthin is hydrolyzed to fucoxanthinol during absorption by Caco-2 human intestinal cells and mice. J Nutr 132:946–951.  https://doi.org/10.1093/jn/132.5.946 CrossRefGoogle Scholar
  51. Sun L et al (2013) Epigenetic regulation of SOX9 by the NF-kappaB signaling pathway in pancreatic cancer stem cells. Stem Cells (Dayton Ohio) 31:1454–1466.  https://doi.org/10.1002/stem.1394 CrossRefGoogle Scholar
  52. Takahashi K, Hosokawa M, Kasajima H, Hatanaka K, Kudo K, Shimoyama N, Miyashita K (2015) Anticancer effects of fucoxanthin and fucoxanthinol on colorectal cancer cell lines and colorectal cancer tissues. Oncol Lett 10:1463–1467.  https://doi.org/10.3892/ol.2015.3380 CrossRefGoogle Scholar
  53. Terasaki M, Maeda H, Miyashita K, Tanaka T, Miyamoto S, Mutoh M (2017) A marine bio-functional lipid, fucoxanthinol, attenuates human colorectal cancer stem-like cell tumorigenicity and sphere formation. J Clin Biochem Nutr 61:25–32.  https://doi.org/10.3164/jcbn.16-112 CrossRefGoogle Scholar
  54. Thorn CF, Oshiro C, Marsh S, Hernandez-Boussard T, McLeod H, Klein TE, Altman RB (2011) Doxorubicin pathways: pharmacodynamics and adverse effects. Pharmacogenet Genom 21:440–446.  https://doi.org/10.1097/FPC.0b013e32833ffb56 CrossRefGoogle Scholar
  55. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A (2015) Global cancer statistics, 2012. CA Cancer J Clin 65:87–108.  https://doi.org/10.3322/caac.21262 CrossRefGoogle Scholar
  56. Trivedi R, Mishra DP (2015) Trailing TRAIL resistance: novel targets for TRAIL sensitization in cancer cells. Front Oncol 5:69.  https://doi.org/10.3389/fonc.2015.00069 CrossRefGoogle Scholar
  57. Vijay K et al (2018) Low-dose doxorubicin with carotenoids selectively alters redox status and upregulates oxidative stress-mediated apoptosis in breast cancer cells. Food Chem Toxicol 118:675–690.  https://doi.org/10.1016/j.fct.2018.06.027 CrossRefGoogle Scholar
  58. Wang J, Chen S, Xu S, Yu X, Ma D, Hu X, Cao X (2012) In vivo induction of apoptosis by fucoxanthin, a marine carotenoid, associated with down-regulating STAT3/EGFR signaling in sarcoma 180 (S180) xenografts-bearing mice. Mar Drugs 10:2055–2068.  https://doi.org/10.3390/md10092055 CrossRefGoogle Scholar
  59. Wang F, Lin J, Xu R (2014) The molecular mechanisms of TRAIL resistance in cancer cells: help in designing new drugs. Curr Pharm Des 20:6714–6722CrossRefGoogle Scholar
  60. Yamamoto K, Ishikawa C, Katano H, Yasumoto T, Mori N (2011) Fucoxanthin and its deacetylated product, fucoxanthinol, induce apoptosis of primary effusion lymphomas. Cancer Lett 300:225–234.  https://doi.org/10.1016/j.canlet.2010.10.016 CrossRefGoogle Scholar
  61. Ye GL, Du DL, Jin LJ, Wang LL (2017) Sensitization of TRAIL-resistant cervical cancer cells through combination of TRAIL and fucoxanthin treatments. Eur Rev Med Pharmacol Sci 21:5594–5601Google Scholar
  62. Yin T et al (2004) Combined effects of As4S4 and imatinib on chronic myeloid leukemia cells and BCR-ABL oncoprotein. Blood 104:4219–4225.  https://doi.org/10.1182/blood-2004-04-1433 CrossRefGoogle Scholar
  63. Yoshiko S, Hoyoku N (2007) Fucoxanthin, a natural carotenoid, induces G1 arrest and GADD45 gene expression in human cancer cells. In Vivo 21:305–309Google Scholar
  64. Zhang L et al (2017) Fucoxanthin provides neuroprotection in models of traumatic brain injury via the Nrf2-ARE and Nrf2-autophagy pathways. Sci Rep 7:46763.  https://doi.org/10.1038/srep46763 CrossRefGoogle Scholar
  65. Zorbas H, Keppler BK (2005) Cisplatin damage: are DNA repair proteins saviors or traitors to the cell? Chembiochem Eur J Chem Biol 6:1157–1166.  https://doi.org/10.1002/cbic.200400427 CrossRefGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Department of Rehabilitation, Wuhan Fourth Hospital, Puai Hospital, Tongji Medical CollegeHuazhong University of Science and TechnologyWuhanChina
  2. 2.Department of Pharmacology, School of Basic Medicine, Tongji Medical CollegeHuazhong University of Science and TechnologyWuhanChina
  3. 3.Tongji Hospital, Tongji Medical CollegeHuazhong University of Science and TechnologyWuhanChina
  4. 4.Medical Examination CenterZibo Sixth Hospital, Zibo Prevention and Treatment Hospital for Occupation DiseasesZiboChina

Personalised recommendations